New small molecule inhibitors, such as MS-444, could not only be used for the treatment of monogenetic type I interferonopathies but also hold potential for the treatment of patients with degenerative diseases associated with cGAS-STING activation, such as Huntington disease, Parkinson disease, and amyotrophic lateral sclerosis (Decout et al, 2021; Kato et al, 2017). Here, CGAS is linked to neurodegenerative disease.